Trough-vs-Peak Target Debate
What a 'Good' Testosterone Level Actually Is, and When to Draw It
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Target ranges derive from guideline recommendations, not a single FDA-defined number
Reference only. Not medical advice.
What can go wrong
Chasing a high peak number pushes men toward supraphysiological exposure, erythrocytosis, and side effects without proven benefit. Conversely, reading a trough as if it were a peak (or vice versa) leads to wrong dose changes. Optimization marketing that promotes ever-higher 'optimal' numbers conflates a bigger lab value with better health, which the outcome data do not support; symptom-guided, safety-bounded dosing is the evidence-aligned approach.
This is something to take to a clinician. The Atlas can tell you what is known about trough-vs-peak target debate in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
A reported testosterone level is meaningless without knowing where in the dosing cycle it was drawn. The Endocrine Society and AUA both target the mid-normal range, but practice splits on whether to dose to the trough (the level just before the next injection) or the peak. Guideline-oriented clinicians often check and target the trough or mid-interval to ensure the patient stays in range at his lowest point; optimization clinics sometimes chase a high peak number. The deeper point is that symptoms and safety, not a single impressive number, define a good level, and that comparing labs across patients is invalid unless draw timing and assay are standardized.
Half the arguments about a TRT lab result are really arguments about when the blood was drawn.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Injectable esters produce a sawtooth concentration curve; the same regimen yields a high number at the post-injection peak and a much lower one at the trough. Targeting the trough (or mid-interval) ensures the patient is adequately replaced even at his lowest point and avoids dose creep driven by a low trough; targeting the peak risks supraphysiological exposure, higher hematocrit, and side effects. For gels and pellets the same logic applies to their respective steady-state and nadir timing. Because assays (immunoassay vs LC-MS/MS) and reference ranges differ, a number is only interpretable with its timing and method attached.
- Injectable curve
- Sawtooth: high peak, low trough
- Trough draw
- Just before next dose
- Peak draw
- ~24-48 h after IM bolus
- Gel
- Morning, several hours after application
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Pushing testosterone above the normal range to hit a peak number increases risk without proven benefit.
What it does to fertility
Target-level choices do not change TRT's suppression of spermatogenesis; fertility preservation requires separate hCG/SERM strategies regardless of trough or peak targeting.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total testosterone drawn at a standardized point (trough/mid-interval for injections; morning for gels)
- Consistent assay (LC-MS/MS preferred when available)
- Hematocrit/hemoglobin
- Symptom review to anchor the target
What people get wrong
Often saidA higher testosterone number is always better
ActuallyBeyond restoring the normal range, higher numbers mainly add side effects (erythrocytosis, etc.) without proven benefit; 'optimal' is normal and symptom-defined, not maximal.
Often saidYou can compare two men's testosterone numbers directly
ActuallyWithout matching draw timing (trough vs peak), formulation, and assay, the numbers are not comparable.
Often saidThe peak level is the one that matters
ActuallyFor safety and adequacy, the trough/mid-interval level is usually the more clinically meaningful target on injectable TRT.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Whether trough or mid-interval targeting yields better outcomes
- How much of 'optimization' targeting above normal is marketing vs benefit
- Best single timepoint for routine monitoring
At a glance
- Guideline target
- Mid-normal range (Endocrine Society / AUA)
- Trough
- Lowest level, just before next dose; common monitoring point for injections
- Peak
- Highest level, days after an IM bolus
- Why timing matters
- Injectable levels swing widely across the interval
- What actually defines 'good'
- Symptom relief and safety, not a single high number
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Trough-vs-Peak Target Debate. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Endocrine Society Clinical Practice Guideline (Bhasin et al., JCEM)2018
Recommends targeting the mid-normal range and standardizing measurement; cautions against supraphysiological levels
AUA Guideline (Mulhall et al.)2018
Targets mid-normal range; emphasizes symptom-based assessment alongside levels